Bar-Sela Gil, Goldberg Hadassah, Beck Dan, Amit Amnon, Kuten Abraham
Department of Oncology, Rambam Medical Center and Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
Anticancer Res. 2006 Jan-Feb;26(1B):709-13.
Malignant ascites is a major problem in the management of advanced stages of certain malignancies. The possibility of reducing the accumulation of ascites by intraperitoneal injections of a Viscum album extract (Iscador M) was evaluated.
Twenty-three patients, with end-stage malignancies of varying histology, requiring repeated peritoneal punctures, were eligible for analysis. The time-interval between the first two punctures was measured and defined as the baseline. Following each subsequent puncture, Iscador M 10 mg was injected intraperitoneally. The intervals between later punctures were compared to previous intervals.
Following the first injection, the median time-interval between injections increased from 7 to 12 days, reaching 13 days after the second injection. No toxicity was observed.
This phase II study suggests that installation of Iscador M into the peritoneal cavity may reduce the need for repeated punctures. A randomized trial is needed to confirm these promising preliminary results.
恶性腹水是某些晚期恶性肿瘤治疗中的一个主要问题。评估了通过腹腔注射欧洲红豆杉提取物（Iscador M）减少腹水积聚的可能性。
23例患有不同组织学类型的晚期恶性肿瘤且需要反复进行腹腔穿刺的患者符合分析条件。测量并将前两次穿刺之间的时间间隔定义为基线。在随后的每次穿刺后，腹腔内注射10 mg Iscador M。将后续穿刺之间的间隔与先前的间隔进行比较。
首次注射后，注射之间的中位时间间隔从7天增加到12天，第二次注射后达到13天。未观察到毒性。
这项II期研究表明，将Iscador M注入腹腔可能减少反复穿刺的需求。需要进行一项随机试验来证实这些有前景的初步结果。
